Secondary prevention after infarction: Therapeutic efficiency - Cost-benefit relation;Sekundärprävention nach herzinfarkt: Therapeutische effizienz-kosten-nutzen-relation

Internist

Volumn 42, Issue 5, 2001, Pages 713-719

  Kreuzer, J ^a   Kubler W ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

COST BENEFIT ANALYSIS; DRUG EFFICACY; HEART INFARCTION; HUMAN; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; COST-BENEFIT ANALYSIS; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 0035023761     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050812     Document Type: Review

References (36)

1. 1. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106
2. 2. Beta-Blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714
3. 3. Cairns JA, Markham BA (1995) Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction. JAMA 273:965-967
4. 4. Frishman WH, Furberg CD, Friedewald WT (1984) Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 310:830-837
5. 5. Gibson RS, Boden WE (1996) Calcium channel antagonists: friend or foe in postinfarction patients? Am J Hypertens 9:1725-1765
6. 6. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC (1988) Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 319:152-157
7. 7. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico (1994) GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115-1122
8. 8. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (1997) Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 336:332-336
9. 9. Kober L, Torp-Pedersen C, Carlsen JE et al. (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670-1676
10. 10. Kubler W (2000) Treatment of cardiac diseases: evidence based or experience based medicine? Heart 84:134-136
11. 11. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J (1994) Cost-effectiveness analysis in heart disease, Part I: General principles. Prog Cardiovasc Dis 37:161-184
12. 12. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J (1995) Cost-effectiveness analysis in heart disease, Part II: Preventive therapies. Prog Cardiovasc Dis 37:243-271
13. 13. LePen C, Lilliu H, Keller T, Fiessinger S (1998) The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 13:49-58
14. 14. Maseri A (1998) Evidence-based medicine: progress but not a final solution. Clin Cardiol 21:463-464
15. 15. McMurray JJ, McGuire A, Davie AP, Hughes D (1997) Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 18:1411-1415
16. 16. Mehta RH, Eagle KA (1998) Secondary prevention in acute myocardial infarction. BMJ 316:838-842
17. 17. Olsson G, Levin LA, Rehnqvist N (1987) Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. BMJ 294:339-342
18. 18. Ople LH, Yusuf S, Kubler W (2000) Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis 43:171-196
19. 19. Pedersen TR, Kjekshus J, Berg K et al. (1996) Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 93:1796-1802
20. 20. Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 327:669-677
21. 21. Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
22. 22. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
23. 23. Schadlich PK, Brecht JG (1997) Kosten-Wirksamkeits-Analyse der Reinfarktprophylaxe mit niedrig dosierter Acetylsalicylsäure: Modellrechnung. Soz Praventivmed 42:114-120
24. 24. Schadlich PK, Huppertz E, Brecht JG (1998) Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 14:653-669
25. 25. Szucs TD, Berger K, Marz W, Schafer JR (2000) Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial. Herz 25:487-494
26. 26. Szucs TD, Guggenberger G, Berger K, Marz W, Schafer JR (1998) Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study. Herz 23:319-329
27. 27. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828
28. 28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357
29. 29. The Norwegian Multicenter Study Group (1981)Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801-807
30. 30. Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW (1998) Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 19 (Suppl):C59-C65
31. 31. Tsevat J, Duke D, Goldman L et al. (1995) Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 26:914-919
32. 32. van Bergen PF, Jonker JJ, van Hout BA, van Domburg RT, Deckers JW, Azar AJ, Hofman A (1995) Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 273:925-928
33. 33. Wilcox RG, Hampton JR, Banks DC et al. (1986) Trial of early nifedipine in acute myocardial infarction: theTRENT study. BMJ 293: 1204-1208
34. 34. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371
35. 35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153
36. 36. Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 260:2088-2093